Reducing vascular leakage

Reducing vascular leakage refers broadly to therapeutic strategies aimed at preventing excessive movement of plasma proteins and fluids from blood vessels into tissues—a hallmark feature in conditions such as inflammation, tumor progression, sepsis-induced shock, and acute lung injury. This process is regulated by multiple molecular players: The most prominent mediator identified is Vascular Endothelial Growth Factor A (VEGF-A, also known historically as Vascular Permeability Factor/VPF), which acts primarily through its receptors on endothelial cells—especially VEGFR2—to increase microvascular permeability by disrupting cell-cell junctions. Other key regulators include: Endothelial adhesion molecules like VE-cadherin at adherens junctions—whose destabilization increases leakiness. Ion channels such as members of the transient receptor potential canonical (TRPC) family that mediate calcium influx leading to cytoskeletal changes affecting barrier function. Pro-inflammatory mediators including histamine and bradykinin. Therapeutic approaches focus on blocking these pathways—for example with anti–VEGF antibodies in cancer therapy—or enhancing barrier-stabilizing signals such as sphingosine‐1‐phosphate analogues. Because "reducing vascular leakage" does not denote one specific protein/receptor but encompasses several targets within complex signaling networks controlling endothelial barrier integrity, it should not be treated as a canonical drug target. In summary: "Reducing vascular leakage" describes an important therapeutic objective involving multiple molecular targets—not itself a discrete molecule/receptor—and thus should be flagged for correction if entered into structured drug-target databases. Key underlying targets include Vascular Endothelial Growth Factor A (VEGF-A) and its receptors among others involved in regulating endothelial cell junction integrity.

Mechanisms to reduce vascular leakage include inhibition of pro-permeability factors like VEGF-A/VEGFR signaling, stabilization of endothelial junctions via modulation of cadherins or cytoskeletal elements, and blockade of inflammatory mediators such as histamine/bradykinin/TRPC channels.